Important achievements from across our portfolio of companies helped drive record revenue and continued success in the opening months of 2019. Medical Marijuana, Inc. and our portfolio of companies and investments continued our upward trend in the first fiscal quarter...
Medical Marijuana, Inc. investment AXIM® Biotechnologies looks to expand impressive intellectual property portfolio with patent on cannabinoid chewing gum for migraines. Leading cannabinoid research and new drug development company AXIM® Biotechnologies recently filed...
This 4/20, we look at how our family of companies have helped to support the cannabis industry, consumers, and patients around the world. The cannabis industry and cannabis enthusiasts pause this 4/20 to celebrate all things cannabis, including the rapid expansion of...
Recent agreement with research organization initiates studies on potential cannabinoid treatments for drug-related psychosis and chemotherapy-related nausea in cancer and AIDS patients. Medical Marijuana, Inc. investment AXIM® Biotechnologies has taken an important...
Medical Marijuana, Inc. rides momentum from first half of the year to pass last year’s revenue numbers with just five months left in 2018 Medical Marijuana, Inc. started off the year on the right foot in January – hitting record revenue numbers for the month. It is a...
SAN DIEGO, Feb. 28, 2018 — Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced that its major investment company AXIM® Biotechnologies (OTC:AXIM) (“AXIM”) has successfully executed their...
